Dutch inhaled drug developer PureIMS said that it has initiated a Phase 1 clinical trial of its Amikacin Cyclops DPI, which it is developing for the treatment of drug susceptible tuberculosis. The single ascending dose study is expected to enroll eight tuberculosis patients, with results anticipated later this year.
The dry powder amikacin formulation is delivered via PureIMS’s Cyclops pre-loaded, disposable DPI. PureIMS has a number of candidates based on the Cyclops platform in its pipeline, with several already in clinical development, including levodopa for Parkinson’s Disease and tobramycin for CF.
Principal investigator Onno Akkerman of the University of Groningen commented, “Positive results using inhaler formulations could dramatically expand amikacin’s clinical utility by immediate reduction of the contagiousness of Mycobacterium tuberculosis. We believe it is important to understand how amikacin works via the Cyclops delivery platform in order to fully realize and leverage its clinical potential for patients with TB.”
Read the PureIMS press release.
